We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.79 | -0.62% | 127.47 | 128.48 | 127.18 | 128.11 | 6,221,929 | 01:00:00 |
From May 2019 to May 2024
By Colin Kellaher
Merck & Co. (MRK) on Monday said the U.S. Food and Drug Administration accepted and granted priority review for a supplemental biologics license application for the cancer drug Keytruda in head and neck cancer.
The Kenilworth, N.J., drug maker said the sBLA seeks approval for Keytruda as monotherapy or in combination with chemotherapy for the first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma.
Merck said the sBLA filing is partly based on data from a phase 3 study in which Keytruda showed a significant improvement in overall survival compared with the standard of care.
The FDA set a target action date of June 10, Merck said.
Keytruda, a cancer drug that harnesses a patient's immune systems to fight tumors, is already marketed to treat lung, skin, bladder and other cancers.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
February 11, 2019 07:17 ET (12:17 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
